A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry
- 17 August 2013
- journal article
- Published by Elsevier BV in Journal of Chromatography B
- Vol. 937, 33-43
- https://doi.org/10.1016/j.jchromb.2013.08.013
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Long-term safety of sorafenib in advanced renal cell carcinoma: Follow-up of patients from phase III TARGETEuropean Journal Of Cancer, 2010
- Marginal increase of sunitinib exposure by grapefruit juiceCancer Chemotherapy and Pharmacology, 2010
- Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2010
- A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal TumorsClinical Cancer Research, 2009
- Phase I Trial of Pazopanib in Patients with Advanced CancerClinical Cancer Research, 2009
- Phase I and Pharmacokinetic Studies of Erlotinib Administered Concurrently with Radiotherapy for Children, Adolescents, and Young Adults with High-Grade GliomaClinical Cancer Research, 2009
- Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS studyBlood, 2008
- Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialThe Lancet, 2006
- Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I TrialJournal of Clinical Oncology, 2002
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001